The global leader in manufacturing veterinary medicines, Merck Animal Health has recently announced the launch of the first and only FDA-approved Nonsteroidal Anti-inflammatory Drug (NSAID). Approved for controlling pain and fever acquired from bovine respiratory disease (BRD) and foot rot, Banamine® Transdermal (flunixin transdermal solution) was introduced at the National Cattlemen’s Beef Association Convention in February this year, cite sources.
As per reliable reports, Merck has been taking the first steps into developing an all-new market in the overall healthcare and medical devices industry. The New Jersey headquartered firm has introduced three new vaccines for beef producers over the last one year namely Whisper stethoscope, Revalor XH, and Banamine Transdermal. Out of these high-grade drugs, Banamine Transdermal is said to possess the capability of revolutionizing pain alleviation methods for cattle producers.
Speaking on the launch of new vaccine, Merck Animal Health product manager for Banamine Transdermal, Chance Morrow was quoted stating that the firm obtained an old product that has been around since the mid-1970s and reinvented a completely new vaccine out of it. He further stated that the idea to manufacture this pour-on commenced 12 years ago.
While researching to find the best formulation to deliver Banamine effectively and safely through the skin, Merck had reportedly tested numerous compounds. Furthermore, the vaccine has been strongly discouraged from being used on any other animal species as it has been formulated to penetrate cow-hide.
Reportedly, Merck has further planned to carry on clinical trials for restricting pain from other procedures and common diseases in beef cattle.
According to industry experts, the launch of Banamine Transdermal in the healthcare and medical devices market is a step in the right direction, given that the vaccine aims to meet the high standards of animal welfare practices which are being followed across the globe.
